This legislation aims to enhance the affordability and accessibility of prescription drugs for seniors enrolled in Medicare, particularly focusing on generic drugs and biosimilar products. It seeks to ensure that Medicare prescription drug plans and Medicare Advantage plans include lower-cost alternatives in their formularies, thereby reducing out-of-pocket costs for beneficiaries who rely on these medications. Starting January 1, 2028, the law mandates that if a drug plan includes a brand-name drug, it must also include all cheaper generic versions.